SOUTHWEST ONCOLOGY GROUP

南加州大学(USC)及其综合癌症 该中心自1987年以来一直是西南肿瘤学小组的成员， 在评估机构优势和承诺后加入 全面整合洛杉矶县(LAC)+的临床活动 南加州大学医院的研究机会。在接下来的5年里，Dr。 佛朗哥·穆贾获得了广泛的机构支持 多学科参与西南肿瘤学小组项目， 提高能力，使LAC+USC的少数族裔人口参与 这样的审判。优势包括：1)经验丰富、敬业的临床 调查支助办公室提供最佳数据输入和检索， 质量控制，以及对羽翼未丰的社区的监督 洛杉矶地区合作小组外展计划(CGOPs)，2)癌症 在临床试验和基础研究方面有深度的中心项目和3) 在乳腺癌辅助试验中的具体贡献 胃肠道肿瘤的多因素研究，血液学和 艾滋病相关肿瘤、妇科肿瘤的局部治疗和药物 黑色素瘤的药理学、生物疗法、系统疗法 肺癌与骨和软组织的临床病理研究 肉瘤。未来的努力将集中在整合其他 多学科参与服务，确保少数群体及时参与 患者进入，基础和临床研究交叉受精。

The University of Southern California (USC) and its Comprehensive Cancer Center have been members of the Southwest Oncology Group since 1987, having joined after assessment of institutional strengths and commitment to fully integrate clinical activities of the Los Angeles County (LAC)+ USC Hospital into research opportunities. In the ensuing 5 years, Dr. Franco Muggia has obtained broad institutional support for multidisciplinary involvement in Southwest Oncology Group programs, with increasing capabilities to involve minority populations in LAC + USC into such trials. Strengths include: 1) an experienced and dedicated Clinical Investigations Support Office providing optimal data entry and retrieval, quality control, as well as supervision of the fledgling community Cooperative Group Outreach Programs (CGOPs) in the LA area, 2) Cancer Center programs with depth in clinical trials and basic research and 3) specific contributions in breast cancer adjuvant trials, in gastrointestinal cancer multimodality research, hematologic and AIDS-related neoplasia, gynecologic cancer locoregional therapy and drug pharmacology, biological therapy of melanoma, systemic therapy in pulmonary cancer, and clinico-pathologic study of bone and soft tissue sarcomas. Future efforts will concentrate on consolidating additional multidisciplinary participation services for ensuring timely minority patient entry, and cross-fertilization of basic and clinical research.